Synthetic Ascendancy

The job-to-be-done here is sharp: help rare disease sponsors avoid FDA Complete Response Letters by validating their external control arms before submission. The REGENXBIO example and the $800K/day stat do real work selling urgency, and the "1.1% conduct quantitative bias analysis" number frames a clear gap. My question is who exactly inside these organizations picks up this tool -- is it the biostatistician, the regulatory affairs lead, or the VP of clinical development? That answer changes your whole go-to-market, and the page doesn't address it yet. The hero headline "Your external control arm isn't ready" is strong and confrontational in a good way, but the two CTAs compete with each other without signaling what "Obtain a Sample Output" actually delivers. I'd consider making the sample output the primary path -- in a space this specialized, showing one worked example of an Evidence Support Score would do more to convert than any amount of copy. The page reads like a white paper right now; tightening it toward a single buyer persona and leading with that sample output would sharpen the whole funnel.